Cirrhosis of liver. Fibrosis and cirrhosis of liver
Conditions
Interventions
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cirrhotic patient Satisfaction for participation in the research project
Exclusion criteria
Exclusion criteria: Pregnancy (in case of selecting a female patient)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Child-Pugh score. Timepoint: Baseline and after 3 month. Method of measurement: Child-Pugh scoring system.;Model for End-Stage Liver Disease (MELD) score. Timepoint: Baseline and after 3 month. Method of measurement: Calculated as follows: 3.78 x ln[serum bilirubin(mg/dL)] + 11.2 x ln[INR] + 9.57 x ln[serumCr(mg/dL)] + 6.43. | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver enzymes (including AST, ALT, ALP, Bilirubin total and direct). Timepoint: Baseline and after 3 month. Method of measurement: Blood test.;Ferritin. Timepoint: Baseline and after 3 month. Method of measurement: Blood test.;Creatinine. Timepoint: Baseline and after 3 month. Method of measurement: Blood test.;Protein. Timepoint: Baseline and after 3 month. Method of measurement: Blood test.;Albumin. Timepoint: Baseline and after 3 month. Method of measurement: Blood test.;Coagulation test (PT, PTT, INR). Timepoint: Baseline and after 3 month. Method of measurement: Blood test.;Volume of ascitis. Timepoint: Baseline and after 3 month. Method of measurement: Sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Emadzadeh
Mashhad University of Medical Sciences
Outcome results
None listed